S

    Sol Gel Technologies Ltd (SLGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $68.81
    -3.76 (-5.18%)

    Market Cap: $225.28M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(24/35)
    Avg Surprise
    +18.31%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-3.01
    Range$-3.01 - $-3.01
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-3.01+0.0%
    60d ago$-3.45-14.6%
    30d ago$-2.58+14.3%
    7d ago$-2.58+14.3%
    Current$-3.01
    Revenue Consensus
    $200000
    Range$200000 - $200000
    1 analysts
    Dec 31, 2026
    EPS Consensus$-1.29
    Range$-3.60 - $1.01
    2 analysts
    Revenue Consensus
    $-780670
    Range$-1250000 - $-542000
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.29---
    Sep 26EST
    		-$-3.01---
    Jun 26
    		$-1.13N/A+51.08%Beat-127.1%
    Mar 26
    		$-1.31$-1.63+19.63%Beat-524.1%
    Dec 25
    		$-1.06$0.40-365.00%Miss-10500.0%
    Sep 25
    		$-2.13$-2.09-1.91%Miss-2030.0%
    Jun 25
    		$4.17$-0.70+695.71%Beat+495.7%
    Mar 25
    		$-0.21$-0.12-74.92%Miss+8.7%
    Dec 24
    		$-0.01N/A+90.91%Beat+99.4%
    Sep 24
    		$-0.10N/A+80.00%Beat+95.2%
    Jun 24
    		$0.70N/A+136.84%Beat+131.8%
    Mar 24
    		$-0.23$-0.15-53.33%Miss+94.4%
    Dec 23
    		$-1.70$-1.75+2.86%Beat-580.0%
    Sep 23
    		$-2.10$-2.30+8.70%Beat-40.0%
    Jun 23
    		$-2.20$-2.55+13.73%Beat-2100.0%
    Mar 23
    		$-4.10$-2.15-90.70%Miss-70.8%
    Dec 22
    		$-0.25$-0.12-108.33%Miss-141.0%
    Sep 22
    		$-1.50$-0.65-130.77%Miss-400.0%
    Jun 22
    		$-0.10N/A+89.69%Beat+97.1%
    Mar 22
    		$-2.40$-2.90+17.24%Beat-33.3%
    Dec 21
    		$0.61$0.41+48.78%Beat+317.9%
    Sep 21
    		$0.50N/A+115.15%Beat+113.5%
    Jun 21
    		$-3.50$-1.83-91.26%Miss-12.9%
    Mar 21
    		$-1.80N/A+60.61%Beat+45.5%
    Dec 20
    		$-0.28$-0.41+31.71%Beat+15.2%
    Sep 20
    		$-3.70$-5.17+28.43%Beat+0.0%
    Jun 20
    		$-3.10$-3.77+17.77%Beat-19.2%
    Mar 20
    		$-3.30$-4.00+17.50%Beat-1000.0%
    Dec 19
    		$-0.33$-0.34+2.94%Beat+94.8%
    Sep 19
    		$-3.70$-2.60-42.31%Miss+7.5%
    Jun 19
    		$-2.60$-2.77+6.14%Beat+27.8%
    Mar 19
    		$-0.30$-0.60+50.00%Beat+92.3%
    Dec 18
    		$-6.40$-5.85-9.40%Miss-635.6%
    Sep 18
    		$-4.00$-5.72+30.07%Beat+45.9%
    Jun 18
    		$-3.60$-5.10+29.41%Beat-407.0%
    Mar 18
    		$-3.90$-4.17+6.47%Beat-1047.1%
    Dec 17
    		$-0.87$-0.61-42.62%Miss-
    Sep 17
    		$-7.40$0.00N/AMiss-
    Jun 17
    		$-0.71$0.00N/AMiss-
    Mar 17
    		$-0.34$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-12.22EV/EBITDA0.24x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-704.00%
    ROE-40.80%ROICN/A
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio10.37xQuick Ratio10.37x
    Trading Statistics
    Beta1.16Avg Volume64.48K
    52-Week High$97.9752-Week Low$22.04

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$77.71
    SMA 20$80.47
    SMA 50$78.76
    SMA 200$68.49
    EMA 10$76.84
    EMA 20$78.70
    EMA 50$78.56
    EMA 200$66.33

    MACD

    Line: -1.58Signal: -0.28Hist: -1.31

    ADX

    ADX: 18.7+DI: 18.0-DI: 29.6

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down100.0
    PSAR$90.41

    Bollinger Bands

    Upper Band$91.15
    Lower Band$69.78
    %B Position2655%(Upper)
    Band Width-0.05

    RSI (14-Day)

    Neutral
    37.2

    Momentum Oscillators

    Stoch %K20.9
    Stoch %D33.3
    Williams %R-89.2
    ROC (10d)-18.8%
    Momentum-15.88
    CCI (20d)-193.3
    MFI (14d)28.9

    Volatility Measures

    ATR (14d)$6.35(9.2%)
    StdDev (20d)5.34
    Hist Vol92.1%(High)

    Volume Flow

    VWAP$70.32
    OBV7.3M
    AD Line515.1M
    CMF (20d)-0.311

    Volume Metrics

    Avg Vol (20d)65.1K
    Vol Ratio2.3x(High)
    VWMA (20d)$80.26

    Pivot Points

    R3$86.92
    R2$83.81
    R1$78.19
    Pivot Point$75.08
    S1$69.46
    S2$66.35
    S3$60.73

    Advanced Oscillators

    TSI-7.44
    Ultimate Osc34.5
    KST-22.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$591,000$108,000$696,000$400,000$17.26M$1.03M$278,000$5.36M$5.43M$466,000$447,000$213,000
    Cost of RevenueN/AN/AN/AN/AN/A$278,000N/A$-7,828,000$2.44M$5.34M$4.17M$4.67M
    Gross Profit$591,000$108,000$696,000$400,000$17.26M$1.03MN/A$5.36M$5.43M$466,000$-3,724,000$213,000
    Operating Expenses$4.75M$3.96M$4.11M$6.69M$6.03M$10.10M$6.38M$6.19M$3.81M$-6,246,000$1.68M$6.52M
    R&D$3.72M$2.79M$3.58M$5.73M$4.65M$8.84M$5.20M$4.82M$2.44M$5.34M$4.17M$4.67M
    SG&A$0$1.18M$577,000$957,000$1.39M$1.26M$1.18M$1.37M$1.37M$1.83M$1.72M$1.86M
    Operating Income$-4,162,000$-3,855,000$-3,411,000$-6,288,000$11.23M$-9,069,000$-6,099,000$-828,000$1.62M$6.71M$-5,407,000$-6,307,000
    Interest Income$0$128,000$424,000$346,000$380,000$261,000$253,000$462,000$352,000$368,000$571,000$596,000
    Interest Expense$0$0$0$0$0$0$0$0$0$13.06M$0$0
    Income Before Tax$-3,681,000$-3,727,000$-2,987,000$-5,942,000$11.61M$-8,808,000$-5,846,000$-366,000$1.98M$-6,344,000$-4,836,000$-5,711,000
    Income Tax Expense$0$0$0$0$0$0$0$0$-62,500$-85,501$-1$-140,500
    Net Income$-3,681,000$-3,727,000$-2,987,000$-5,942,000$11.61M$-8,808,000$-5,846,000$-366,000$1.98M$-6,344,000$-4,836,000$-5,711,000
    EBITDA$-4,162,000$-3,855,000$-3,411,000$-5,942,000$11.23M$-9,069,000N/A$-490,000$1.62M$6.71M$-5,321,500$-6,307,000
    EBITN/AN/AN/AN/AN/A$-5,846,000N/A$-828,000$1.62M$-6,712,000$-5,407,000$-6,307,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLGL

    News

    Sol-Gel Technologies: Runway To Fund Cash Requirements Into 1Q 2028 >SLGL

    Sol-Gel Technologies (SLGL) has extended its cash runway to fund operations until the first quarter of 2028, primarily due to cost reductions and the out-licensing of its drug candidate, serlopitant. This extension provides financial stability for the company as it continues its clinical development programs.

    Moomoo•8/20/26•
    Bullish

    Sol Gel Tech earnings beat by $2.20, revenue fell short of estimates

    Sol Gel Technologies (NASDAQ: SLGL) reported its second-quarter earnings, beating analyst EPS estimates by $2.20 with an EPS of $-1.1300 against an expected $-3.3300. However, the company's revenue of $591K fell short of the consensus estimate of $1.2M. Despite the mixed results, Sol Gel Tech's stock has shown strong performance, up 2.4200% in the last three months and 205.2300% over the last 12 months, with its financial health rated as "great performance" by InvestingPro.

    Investing.com•8/20/26•
    Somewhat-Bullish

    Sol-Gel Technologies Releases Q2 2026 Financial Results

    Sol-Gel Technologies Ltd. reported a significant financial downturn in Q2 2026, with a loss of $1.13 per share and a net loss of $3.7 million, a sharp reversal from earnings in the prior year. Revenue plummeted by 96.6% due to reduced commercial income as the company invests heavily in its clinical pipeline for dermatological treatments. Despite the setback, analysts maintain a generally positive outlook with seven buy ratings.

    AlphaStreet•8/20/26•
    Bearish

    Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS

    Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly earnings, significantly beating analyst expectations with a loss of $1.13 per share against an estimated loss of $2.36, and revenue of $0.59 million against a $0.07 million forecast. Despite continued unprofitability and stock volatility, analyst sentiment remains a "Moderate Buy" with an average price target of $197.50, and insiders have increased their holdings.

    MarketBeat•8/20/26•
    Bullish

    Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

    Sol-Gel Technologies announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates. The company's pivotal Phase 3 clinical trial for SGT-610 in Gorlin syndrome is progressing, with top-line results expected in late November 2026, and patient dropout rates are lower than anticipated. Sol-Gel also initiated new studies for patidegib gel in high-frequency basal cell carcinoma and as a neo-adjuvant in BCC surgery, while filing a provisional patent for an intra-cystic injectable treatment for odontogenic keratocysts, expanding the potential applications of its hedgehog inhibitor expertise.

    The Manila Times•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About SLGL

    Does SLGL pay dividends?
    Sol Gel Technologies Ltd (SLGL) does not currently pay a regular dividend.
    What is SLGL's market cap?
    Sol Gel Technologies Ltd (SLGL) has a market capitalization of $225.28M with a current stock price of $68.81.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In